First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study

First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study

BackgroundGastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a group of rare but highly aggressive malignancies. The standard chemotherapy regimens composed of etoposide and cisplatin/carboplatin (EP/EC) are of limited efficacy. This prospective, multicenter, phase II study is conducted to...

Full description

Bibliographic Details
Main Authors: Xiaofen Li, Qing Ma, Chen Chang, Hao Li, Dan Cao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
gastroenteropancreatic neuroendocrine carcinoma
camrelizumab
immunotherapy
first line
study protocol
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.958905/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.958905/full

Similar Items